Testing effectiveness (Phase 2)Study completedNCT00851890
What this trial is testing
Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
Who this might be right for
Chronic Hepatitis C Virus Infection
AbbVie (prior sponsor, Abbott) 30